Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-18

Nasal Pandemic Influenza Vaccine

Objective

The project is being undertaken in response to the need to develop an effective, user friendly, heat stable vaccine to control the highly pathogenic form of avian influenza virus (H5 and H7 subtypes) which has the potential to cause another global influenza pandemic. The overall objective of this programme is to develop a nasal avian influenza vaccine using ChiSys® (chitosan), which is a chitosan-based technology of Archimedes Development Ltd.. Chitosan has already been tested with several nasally delivered antigens pre-clinically and clinically with excellent results. The most effective way of controlling a pandemic flu would be via the nasal route as this route is advantaged to generate both systemic and mucosal antibodies; the latter allowing virus control at its point of entry. In comparison the currently used injection route cannot achieve the mucosal response. Intranasal vaccination has further advantages: avoids the need for injection and safe disposal of syringes, eliminate the risk of HIV transmission through re-use or accidental contact with body fluids, have greater public compliance and well-suited to rapid mass global vaccination programmes. The scientific objectives of the project are: induce both systemic and mucosal immunity, evaluation of efficacy and toxicity in preclinical studies, evaluation of efficacy and safety profile in humans, provide a substantial level of cross-immunity against a drifted strains of H5 or H7, effective at low dose to meet the global demands from limited vaccine stockpiles, thermal stability so as to avoid refrigeration for storage and transportation and user friendly vaccine applicator. The consortium members have extensive experience in their specialist fields which would enable the success of this project. ChiSys® would be an excellent candidate for developing an intranasal pandemic influenza vaccine to provide a quantum leap in successfully combating pandemic influenza globally.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP7-HEALTH-2007-A
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CP-FP - Small or medium-scale focused research project

Coordinator

ARCHIMEDES DEVELOPMENT LIMITED
EU contribution
€ 977 621,40
Address
Albert Einstein Centre Nottingham Science and Technology Park
NG7 2TN Nottingham
United Kingdom

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (7)

My booklet 0 0